Evidence map›Paper›PMID 41203980›Full record

ArticleCardiovascular and interventional radiology2026

Intra-arterial Hepatic

Ruben K Fakkert, Arthur J A T Braat, Bart de Keizer, Rutger C G Bruijnen, Cheryl P Bruijnen, Alex J Poot, Maarten L J Smits, Marnix G E H Lam

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ruben K FakkertDepartment of Nuclear Medicine and Radiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. r.k.fakkert@umcutrecht.nl.ORCID http://orcid.org/0000-0002-9614-0723
Arthur J A T BraatDepartment of Nuclear Medicine and Radiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
Bart de KeizerDepartment of Nuclear Medicine and Radiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
Rutger C G BruijnenDepartment of Nuclear Medicine and Radiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
Cheryl P BruijnenDepartment of Medical Oncology, UMC Utrecht, Utrecht, The Netherlands.
Alex J PootDepartment of Clinical Pharmacy, UMC Utrecht, Utrecht, The Netherlands.
Maarten L J SmitsDepartment of Nuclear Medicine and Radiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
Marnix G E H LamDepartment of Nuclear Medicine and Radiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the safety and feasibility of intra-arterial MATERIALS AND

methodsPatients received up to six cycles of

resultsFour patients received 16 cycles (10 intra-arterial, six intravenous). All intra-arterial procedures were technically successful and without periprocedural complications. Toxicity was acceptable and comparable to intravenous treatment, comprising mainly grade 1-2 clinical events with occasional grade 3 biochemical abnormalities, and no grade 4-5 clinical toxicities were observed. PSA decreases occurred in two patients (decrease 24-99%), while two patients had increases. Imaging response was more profound for liver metastasis.

conclusionThese preliminary findings suggest that intra-arterial

Indexed as

Liver NeoplasmsLutetiumProstatic Neoplasms, Castration-ResistantRadioisotopesRadiopharmaceuticalsAgedAged, 80 and overFeasibility StudiesHepatic ArteryHumansInfusions, Intra-ArterialMaleMiddle AgedProstate-Specific AntigenTreatment OutcomeLutetiumLutetium-177PluvictoProstate-Specific AntigenRadioisotopesRadiopharmaceuticals177Lu-PSMA-radioligand therapy (RLT)FeasibilityIntra-arterial hepatic administrationLiver-dominant metastasesMetastatic castration-resistant prostate cancer (mCRPC)PET/CT imagingSafetyTotal lesion PSMA (TL-PSMA)

Identifiers

PMID41203980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.